>>**Entry Name: Octreotide,** BAN, INN, USAN
Synonym(s): Longastatina. Samilstin. Sandostatin. SMS 201-995



CAS Registry Number: 83150-76-9
Related CAS Registry Numbers(s): 88495-44-7 95189-74-5

Molecular Formula: $C_{49}H_{66}N_{10}O_{10}S_2$
Molecular Weight: 1019.253
Accurate Mass: 1018.44048
Percentage Composition: C 57.74%; H 6.53%; N 13.74%; O 15.70%; S 6.29%

Use/Importance: Growth hormone secretion inhibitor. Opiate antagonist used in treatment of GI tract tumours; also used in the treatment of acromegaly
Development Status: Launched 1988
Optical Rotation: $[\alpha]_D^{20}$–42 (c, 0.5 in AcOH)
Other Data: Opt. isomers also known

>>**Derivative:** Acetate salt (1:*x*)
Synonym(s): Octreotide acetate, USAN

CAS Registry Number: 79517-01-4
Hazard & Toxicity: LD_{50} (rat, ivn) 18 mg/kg

>>**Derivative:** 4,4'-Methylenebis(3-hydroxy-2-naphthoate) salt
Synonym(s): Octreotide pamoate, USAN

CAS Registry Number: 135467-16-2
Physical Description: Yellow powder
Optical Rotation: $[\alpha]_D^{20}$+7.5 (c, 0.35 in DMF)

References:

Bauer, W. *et al.*, *Life Sci.*, 1982, **31**, 1133, *(props)*
Wynants, C. *et al.*, *Int. J. Pept. Protein Res.*, 1985, **25**, 608; 615, *(pmr, conformn)*
U.S. Pat., 1985, *Sandoz*, 4 395 403; *CA*, **95**, 187679e, *(synth)*
Pless, J. *et al.*, *Int. Congr. Ser. Excerpta Med.*, 1986, **683**, 319, *(pharmacol)*
Longnecker, J.P., *Drug Intell. Clin. Pharm.*, 1988, **22**, 99, *(rev)*
Katz, M.D. *et al.*, *Clin. Pharm.*, 1989, **8**, 255, *(rev)*
Battershill, P.E. *et al.*, *Drugs*, 1989, **38**, 658, *(rev)*
Metab., Clin. Exp., (Eds. Harris, A.G. *et al*), *Suppl*. 2, 1992, **41**, *(rev)*
Harris, A.G. *et al.*, *Eur. J. Med.*, 1993, **2**, 97, *(rev)*
Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 958
U.S. Pat., 1996, *Sandoz*, 5 538 739; *CA*, **125**, 177407, *(pamoate)*
Gillis, J.C. *et al.*, *Drugs*, 1997, **54**, 681-699, *(rev)*